A closer examination of these cases revealed that clinical implementation was not considered due to worsened health condition of the patient with a CHEK2 p.Thr410MetfsTer15-mutated high-grade ovarian serous adenocarcinoma (recommendation: PARP inhibitor) and due to the application of immune checkpoint inhibitor therapy in the context of a significantly elevated combined positivity score (CPS) of 75 in an ERBB2-amplified (GCN: 25.3) stomach cancer (MTB recommendation: trastuzumab). Here, CHEK2 is linked to ovarian serous adenocarcinoma.